Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

Article Details

Citation

Copy to clipboard

Guerrant W, Patil V, Canzoneri JC, Oyelere AK

Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.

J Med Chem. 2012 Feb 23;55(4):1465-77. doi: 10.1021/jm200799p. Epub 2012 Feb 13.

PubMed ID

22260166 [ View in PubMed

]

Abstract

Strategies to ameliorate the flaws of current chemotherapeutic agents, while maintaining potent anticancer activity, are of particular interest. Agents which can modulate multiple targets may have superior utility and fewer side effects than current single-target drugs. To explore the prospect in cancer therapy of a bivalent agent that combines two complementary chemo-active groups within a single molecular architecture, we have synthesized dual-acting histone deacetylase and topoisomerase II inhibitors. These dual-acting agents are derived from suberoylanilide hydroxamic acid (SAHA) and anthracycline daunorubicin, prototypical histone deacetylase (HDAC) and topoisomerase II (Topo II) inhibitors, respectively. We report herein that these agents present the signatures of inhibition of HDAC and Topo II in both cell-free and whole-cell assays. Moreover, these agents potently inhibit the proliferation of representative cancer cell lines.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
Vorinostat	Histone deacetylase 1	IC 50 (nM)	38	N/A	N/A	Details
Vorinostat	Histone deacetylase 6	IC 50 (nM)	27	N/A	N/A	Details